Skip to main content

Table 7 Trials of mTOR inhibitors in metastatic breast cancer

From: Antiangiogenic therapy for breast cancer

Reference Phase Number of patients Treatment Response (%) PFS (months)
mTOR inhibitor monotherapy
   Chan et al. [78] II (randomised) 109 Temsirolimus (two dose levels) ORR 9 NR
   Ellard et al. [79] II (randomised) 49 (33: daily schedule) Everolimus (two different schedules) ORR 12 (daily schedule) NR
    ORR 0 (weekly schedule) NR NR
mTOR inhibitor plus chemotherapy
   Moulder et al. [81]* I 15 Everolimus + docetaxel RR 0 NR
   Mayer et al. [82] Ib 16 Everolimus + cisplatin + paclitaxel RR 23 NR
mTOR inhibitor plus endocrine therapy
   Carpenter et al. [83] II (randomised) 33: daily Temsirolimus (two schedules) + letrozole PR 27 Not reached
   30: intermittent   CR 3, PR 27 Not reached
   29 Letrozole CR 7 + PR 34 9.2
   Chow et al. [84]* III 556 Temsirolimus + letrozole ORR 27 8.8
   556 Letrozole ORR 27 8.9
  1. *Study terminated due to toxicity. CR, complete response; mTOR, mammalian target of rapamycin; NR, not reported; ORR, overall response rate; PFS, progression free survival; PR, partial response; RR, response rate.